| Literature DB >> 29438689 |
Mariana Salatino1, María Romina Girotti2, Gabriel A Rabinovich3.
Abstract
The clinical efficacy of therapies targeting the PD-1/PD-L1 pathway is still limited. In this issue of Cancer Cell, Li and colleagues identify a PD-L1 glycosylation-based mechanism in triple-negative breast cancer that fosters immunosuppression by enhancing interactions with PD-1. Targeting glycosylated PD-L1 with a drug-conjugated antibody opens new avenues for treatment.Entities:
Mesh：
Substances：
Year: 2018 PMID： 29438689 DOI： 10.1016/j.ccell.2018.01.015
Source DB: PubMed Journal: Cancer Cell ISSN： 1535-6108 Impact factor: 31.743